National Pregnancy Registry for Psychiatric Medications©

Click here for Participation information

The National Pregnancy Registry for Psychiatric Medications is dedicated to evaluating the safety of psychiatric medications such as antidepressants, ADHD medications, and atypical antipsychotics that many people take during pregnancy to treat a wide range of mood, anxiety, executive function, or psychiatric disorders. The goal of this Registry is to gather information on the safety of these medications during pregnancy, as current data is limited.

If you are pregnant and have taken an antidepressant, ADHD medication, or atypical antipsychotic, please click the participation information button above. Individuals with a history of psychiatric illness who are pregnant and have not taken an antidepressant, ADHD medication, or atypical antipsychotic are also welcome to enroll in the Registry.

The National Pregnancy Registry for Atypical Antipsychotics

The National Pregnancy Registry for Antidepressants

The National Pregnancy Registry for ADHD Medications

The National Pregnancy Registry for Sedative-Hypnotics and Other Sleep Medications

Viguera, A. C., Jones, A., Szpunar, M. J., Bernstein, S. N., Killenberg, P. C., Sojka, E. T., Rossa, E. T., Gaccione, P., Freeman, M. P., & Cohen, L. S. (2024). The Risk of Postpartum Hemorrhage with Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors: Preliminary Results from the Massachusetts General Hospital National Pregnancy Registry for Psychiatric Medications. Journal of Women’s Health, 0(0), null. https://doi.org/10.1089/jwh.2024.0033

Swetlik, C., Cohen, L. S., Kobylski, L. A., Sojka, E. T., Killenberg, P. C., Freeman, M. P., & Viguera, A. C. (2024). Effects of Prenatal Exposure to Second-Generation Antipsychotics on Development and Behavior Among Preschool-Aged Children: Preliminary Results From the National Pregnancy Registry for Psychiatric Medications. The Journal of Clinical Psychiatry, 85(1).

Cohen, L. S., Church, T. R., Freeman, M. P., Gaccione, P., Caplin, P. S., Kobylski, L. A., Arakelian, M., Rossa, E. T., Chitayat, D., Hernández-Díaz, S., & Viguera, A. C. (2023). Reproductive Safety of Lurasidone and Quetiapine: Update from the National Pregnancy Registry for Psychiatric Medications. Journal of women’s health (2002), 32(4), 452–462.

Viguera, A. C., McElheny, S. A., Caplin, P. S., Kobylski, L. A., Rossa, E. T., Young, A. V., Gaccione, P., Góez-Mogollón, L., Freeman, M. P., & Cohen, L. S. (2023). Risk of Poor Neonatal Adaptation Syndrome Among Infants Exposed to Second-Generation Atypical Antipsychotics Compared to Antidepressants: Results From the National Pregnancy Registry for Psychiatric Medications. The Journal of clinical psychiatry, 84(1), 22m14492.

Freeman, M. P., Szpunar, M. J., Kobylski, L. A., Harmon, H., Viguera, A. C., & Cohen, L. S. (2022). Pregnancy outcomes after first-trimester exposure to buspirone: prospective longitudinal outcomes from the MGH National Pregnancy Registry for Psychiatric Medications. Archives of women’s mental health, 25(5), 923–928.

Szpunar, M. J., Freeman, M. P., Kobylski, L. A., Caplin, P. S., Gaccione, P., Viguera, A. C., Chitayat, D., Hernández-Díaz, S., & Cohen, L. S. (2022). Risk of major malformations in infants after first-trimester exposure to benzodiazepines: Results from the Massachusetts General Hospital National Pregnancy Registry for Psychiatric Medications. Depression and anxiety, 39(12), 751–759.

Viguera, A. C., Vanderkruik, R., Gaccione, P., Caplin, P. S., Kobylski, L. A., Freeman, M. P., & Cohen, L. S. (2022). Breastfeeding practices among women taking second-generation antipsychotics: findings from the National Pregnancy Registry for Atypical Antipsychotics. Archives of women’s mental health, 25(2), 511–516.

Viguera, A. C., Freeman, M. P., Góez-Mogollón, L., Sosinsky, A. Z., McElheny, S. A., Church, T. R., Young, A. V., Caplin, P. S., Chitayat, D., Hernández-Díaz, S., & Cohen, L. S. (2021). Reproductive Safety of Second-Generation Antipsychotics: Updated Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. The Journal of clinical psychiatry, 82(4), 20m13745.

Freeman, M. P., Viguera, A. C., Góez-Mogollón, L., Young, A. V., Caplin, P. S., McElheny, S. A., Church, T. R., Chitayat, D., Hernández-Díaz, S., & Cohen, L. S. (2021). Reproductive safety of aripiprazole: data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Archives of women’s mental health, 24(4), 659–667.

Freeman, M. P., Goez-Mogollon, L., Sosinsky, A. Z., Church, T. R., McElheny, S. A., Viguera, A. C., & Cohen, L. S. (2019). The impact of obesity on pregnancy outcomes among women with psychiatric disorders: Results from a prospective pregnancy registry. Journal of psychosomatic research, 123, 109735.

Freeman, M. P., Sosinsky, A. Z., Goez-Mogollon, L., Savella, G. M., Moustafa, D., Viguera, A. C., & Cohen, L. S. (2018). Gestational Weight Gain and Pre-pregnancy Body Mass Index Associated With Second-Generation Antipsychotic Drug Use During Pregnancy. Psychosomatics, 59(2), 125–134.

Cohen, L. S., Góez-Mogollón, L., Sosinsky, A. Z., Savella, G. M., Viguera, A. C., Chitayat, D., Hernández-Díaz, S., & Freeman, M. P. (2018). Risk of Major Malformations in Infants Following First-Trimester Exposure to Quetiapine. The American journal of psychiatry, 175(12), 1225–1231.

Freeman, M. P., Farchione, T., Yao, L., Sahin, L., Taylor, L., Huybrechts, K. F., Nonacs, R., Sosinsky, A. Z., Viguera, A. C., & Cohen, L. S. (2018). Psychiatric Medications and Reproductive Safety: Scientific and Clinical Perspectives Pertaining to the US FDA Pregnancy and Lactation Labeling Rule. The Journal of clinical psychiatry, 79(4), 18ah38120.

Freeman, M. P., Góez-Mogollón, L., McInerney, K. A., Davies, A. C., Church, T. R., Sosinsky, A. Z., Noe, O. B., Viguera, A. C., & Cohen, L. S. (2018). Obstetrical and neonatal outcomes after benzodiazepine exposure during pregnancy: Results from a prospective registry of women with psychiatric disorders. General hospital psychiatry, 53, 73–79.

Park, Y., Hernandez-Diaz, S., Bateman, B. T., Cohen, J. M., Desai, R. J., Patorno, E., Glynn, R. J., Cohen, L. S., Mogun, H., & Huybrechts, K. F. (2018). Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes. The American journal of psychiatry, 175(6), 564–574.

Freeman, M. P., Sosinsky, A. Z., Goez-Mogollon, L., Savella, G. M., Moustafa, D., Viguera, A. C., & Cohen, L. S. (2018). Gestational Weight Gain and Pre-pregnancy Body Mass Index Associated With Second-Generation Antipsychotic Drug Use During Pregnancy. Psychosomatics, 59(2), 125–134.

Panchaud, A., Hernandez-Diaz, S., Freeman, M. P., Viguera, A. C., MacDonald, S. C., Sosinsky, A. Z., & Cohen, L. S. (2017). Use of atypical antipsychotics in pregnancy and maternal gestational diabetes. Journal of psychiatric research, 95, 84–90.

Sosinsky, A. Z., Freeman, M. P., Savella, G. M., Cheng, L. J., Viguera, A. C., & Cohen, L. S. (2017). Delusional Pregnancy Presenting to the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Journal of clinical psychopharmacology, 37(4), 472–474.

Patorno, E., Huybrechts, K. F., Bateman, B. T., Cohen, J. M., Desai, R. J., Mogun, H., Cohen, L. S., & Hernandez-Diaz, S. (2017). Lithium Use in Pregnancy and the Risk of Cardiac Malformations. The New England journal of medicine, 376(23), 2245–2254.

Huybrechts, K. F., Hernández-Díaz, S., Patorno, E., Desai, R. J., Mogun, H., Dejene, S. Z., Cohen, J. M., Panchaud, A., Cohen, L., & Bateman, B. T. (2016). Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. JAMA psychiatry, 73(9), 938–946.

Freeman, M. P., Sosinsky, A. Z., Moustafa, D., Viguera, A. C., & Cohen, L. S. (2016). Supplement use by women during pregnancy: data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Archives of women’s mental health, 19(3), 437–441.

Cohen, L. S., Viguera, A. C., McInerney, K. A., Freeman, M. P., Sosinsky, A. Z., Moustafa, D., Marfurt, S. P., Kwiatkowski, M. A., Murphy, S. K., Farrell, A. M., Chitayat, D., & Hernández-Díaz, S. (2016). Reproductive Safety of Second-Generation Antipsychotics: Current Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. The American journal of psychiatry, 173(3), 263–270.

Cohen, L. S., Viguera, A. C., McInerney, K. A., Freeman, M. P., Sosinsky, A. Z., Moustafa, D., Marfurt, S. P., Kwiatkowski, M. A., Murphy, S. K., Farrell, A. M., Chitayat, D., & Hernández-Díaz, S. (2016). Reproductive Safety of Second-Generation Antipsychotics: Current Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. The American journal of psychiatry, 173(3), 263–270.

Cohen, L. S., Viguera, A. C., McInerney, K. A., Kwiatkowski, M. A., Murphy, S. K., Lemon, E. L., & Hernández-Díaz, S. (2015). Establishment of the National Pregnancy Registry for Atypical Antipsychotics. The Journal of clinical psychiatry, 76(7), 986–989.

Freeman, M. P. (2015). Psychotropic medication use during pregnancy: changes to the labeling system and the importance of exposure registries. The Journal of clinical psychiatry, 76(7), 990–991.

Huybrechts, K. F., Palmsten, K., Avorn, J., Cohen, L. S., Holmes, L. B., Franklin, J. M., Mogun, H., Levin, R., Kowal, M., Setoguchi, S., & Hernández-Díaz, S. (2014). Antidepressant use in pregnancy and the risk of cardiac defects. The New England journal of medicine, 370(25), 2397–2407.

Required Sponsorship Disclosures:

Current Sponsors: Alkermes, Inc. (2016-Present); Bristol-Myers Squibb Company (2025-Present); Eisai Inc. (2022-Present); Otsuka America Pharmaceutical, Inc. (2008-Present); Sage Therapeutics (2019-2023, 2024-Present); Supernus Pharmaceuticals (2021-Present).

Past Sponsors: Forest/Actavis/Allergan (2016-2018, declined to sponsor: 2018-Present); Aurobindo Pharma (2020-2022, declined to sponsor: 2022-Present); AstraZeneca Pharmaceuticals (2009-2014, declined to sponsor: 2014-Present); AuroMedics Pharma LLC (2021-2022, declined to sponsor: 2022-Present); Johnson & Johnson/Janssen Pharmaceuticals, Inc (2019-2023, declined to sponsor: 2024-Present) ; Ortho-McNeil-Janssen Pharmaceuticals, Inc (2009-2014, declined to sponsor: 2015-Present); Pfizer, Inc. (2009-2011, declined to sponsor: 2012-Present); Sunovion Pharmaceuticals, Inc. (2011-2023, declined to sponsor: 2024-Present); Teva Pharmaceutical Industries Ltd. (2018-2025; declined to sponsor 2026-Present); Dr. Reddy’s Laboratories, Inc. (2023-2025, declined to sponsor 2026-Present).

Declined to sponsor: AbbVie Inc.; Ajanta Pharma USA Inc.; Apotex Inc.; Arcolab Private Limited; Eli Lilly and Company; Intra-Cellular Therapies, Inc.; Novartis Pharmaceuticals; Qilu Pharmaceutical Co., Ltd.; Vanda Pharmaceuticals Inc; Axsome Therapeutics, Inc.

Funding Information: Manufacturers of psychiatric medications have been approached regarding funding of the National Pregnancy Registry. Regardless of which entities have supported this initiative, all medications in this class are studied. For more information on how to sponsor the Registry, please see the contact information below.

Share: